Molecular and Cellular Pathobiology Integrative Genomic Analyses of Sporadic Clear Cell Renal Cell Carcinoma De fi ne Disease Subtypes and Potential New Therapeutic Targets
暂无分享,去创建一个
K. Nathanson | P. Lal | E. Attiyeh | M. Simon | J. Gordan | B. Wubbenhorst | K. D’Andrea | V. Dondeti | M. Simon
[1] W. Woodward,et al. EZH2 promotes expansion of breast tumor initiating cells through activation of RAF1-β-catenin signaling. , 2011, Cancer cell.
[2] P. A. Futreal,et al. Exome sequencing identifies frequent mutation of the SWI/SNF complex gene PBRM1 in renal carcinoma , 2010, Nature.
[3] P. Schirmacher,et al. Enhancer of zeste homolog 2 (EZH2) expression is an independent prognostic factor in renal cell carcinoma , 2010, BMC Cancer.
[4] Ross S Berkowitz,et al. Up-regulation of stromal versican expression in advanced stage serous ovarian cancer. , 2010, Gynecologic oncology.
[5] J. Testa,et al. Combined classical cytogenetics and microarray‐based genomic copy number analysis reveal frequent 3;5 rearrangements in clear cell renal cell carcinoma , 2010, Genes, chromosomes & cancer.
[6] M. van Engeland,et al. VHL and HIF signalling in renal cell carcinogenesis , 2010, The Journal of pathology.
[7] Zhaohui S. Qin,et al. An integrated network of androgen receptor, polycomb, and TMPRSS2-ERG gene fusions in prostate cancer progression. , 2010, Cancer cell.
[8] W. Kimryn Rathmell,et al. Renal Cell Carcinoma: Where Will the State-of-the-Art Lead Us? , 2010, Current oncology reports.
[9] Howard Y. Chang,et al. The histone demethylase UTX enables RB-dependent cell fate control. , 2010, Genes & development.
[10] Derek Y. Chiang,et al. The landscape of somatic copy-number alteration across human cancers , 2010, Nature.
[11] W. Gregory,et al. Analysis of VHL Gene Alterations and their Relationship to Clinical Parameters in Sporadic Conventional Renal Cell Carcinoma , 2009, Clinical Cancer Research.
[12] Z. Gatalica,et al. Detection of chromosomal aberrations in renal tumors: a comparative study of conventional cytogenetics and virtual karyotyping with single-nucleotide polymorphism microarrays. , 2009, Archives of pathology & laboratory medicine.
[13] Gurpreet W. Tang,et al. Systematic sequencing of renal carcinoma reveals inactivation of histone modifying genes , 2009, Nature.
[14] K. Mimori,et al. Clinicopathological significance of stanniocalcin 2 gene expression in colorectal cancer , 2009, International journal of cancer.
[15] Arianna Di Napoli,et al. Patterns of gene expression and copy-number alterations in von-hippel lindau disease-associated and sporadic clear cell carcinoma of the kidney. , 2009, Cancer research.
[16] Yusuke Nakamura,et al. Stanniocalcin 2 overexpression in castration‐resistant prostate cancer and aggressive prostate cancer , 2009, Cancer science.
[17] G. Kristiansen,et al. Identification of stanniocalcin 2 as prognostic marker in renal cell carcinoma. , 2009, European urology.
[18] A. Belldegrun,et al. Cytogenetic profile predicts prognosis of patients with clear cell renal cell carcinoma. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[19] M. Brunelli,et al. The ‘Stage, Size, Grade and Necrosis’ score is more accurate than the University of California Los Angeles Integrated Staging System for predicting cancer‐specific survival in patients with clear cell renal cell carcinoma , 2009, BJU international.
[20] Brian Keith,et al. HIF-alpha effects on c-Myc distinguish two subtypes of sporadic VHL-deficient clear cell renal carcinoma. , 2008, Cancer cell.
[21] J. Simon,et al. Roles of the EZH2 histone methyltransferase in cancer epigenetics. , 2008, Mutation research.
[22] F. Waldman,et al. Improved Identification of von Hippel-Lindau Gene Alterations in Clear Cell Renal Tumors , 2008, Clinical Cancer Research.
[23] P. Heikkilä,et al. Tumor dormancy: elevated expression of stanniocalcins in late relapsing breast cancer. , 2008, Cancer letters.
[24] H. Zentgraf,et al. The enhancer of zeste homolog 2 gene contributes to cell proliferation and apoptosis resistance in renal cell carcinoma cells , 2008, International journal of cancer.
[25] John D Gordan,et al. HIF-2alpha promotes hypoxic cell proliferation by enhancing c-myc transcriptional activity. , 2007, Cancer cell.
[26] Kristian Helin,et al. The Polycomb group proteins bind throughout the INK4A-ARF locus and are disassociated in senescent cells. , 2007, Genes & development.
[27] M. Simon,et al. Hypoxia-inducible factors: central regulators of the tumor phenotype. , 2007, Current opinion in genetics & development.
[28] Patrick H. Maxwell,et al. Contrasting Properties of Hypoxia-Inducible Factor 1 (HIF-1) and HIF-2 in von Hippel-Lindau-Associated Renal Cell Carcinoma , 2005, Molecular and Cellular Biology.
[29] J. Slingerland,et al. The roles of versican V1 and V2 isoforms in cell proliferation and apoptosis. , 2005, Molecular biology of the cell.
[30] W. Kaelin,et al. Inhibition of HIF2α Is Sufficient to Suppress pVHL-Defective Tumor Growth , 2003, PLoS biology.
[31] T. Wight,et al. Versican: a versatile extracellular matrix proteoglycan in cell biology. , 2002, Current opinion in cell biology.
[32] M. Karno,et al. Renal cell carcinoma. , 1956, Bulletin. Tufts-New England Medical Center.